Cerus share price today

(CERS)

Cerus share price is $1.66 & ₹141.55 as on 28 Dec 2024, 2.30 'hrs' IST

$1.66

▲

0.08

(5.06%)

Market is closed - opens 8 PM, 27 Dec 2024

View live Cerus share price in Dollar and Rupees. Guide to invest in Cerus from India. Also see the sentimental analysis on Indian investors investing in Cerus. Get details on the Indian mutual funds that are investing in Cerus. Get Analyst recommendations and forecasts along with all the Cerus's financials.

Cerus share price movements

Today's Low: $1.56
Today's High: $1.67
$1.66
6.02%
Downside
Day's Volatility :6.31%
Upside
0.3%
52 Weeks Low: $1.38
52 Weeks High: $2.59
$1.66
17.17%
Downside
52 Weeks Volatility :46.81%
Upside
35.78%

Cerus Returns

Period	Cerus Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	-9.71%	-9.0%	0.0%
6 Months	-10.23%	-4.6%	0.0%
1 Year	-30.09%	3.0%	0.0%
3 Years	-76.7%	0.0%	-21.1%

Cerus Key Statistics

in dollars & INR

Previous Close	$1.58
Open	$1.58
Today's High	$1.665
Today's Low	$1.56
Market Capitalization	$293.4M
Today's Volume	$562.8K
52 Week High	$2.585
52 Week Low	$1.375
Revenue TTM	$176.2M
EBITDA	$-9.6M
Earnings Per Share (EPS)	$-0.11
Profit Margin	-11.19%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-38.31%

How to invest in Cerus from India?

It is very easy for Indian residents to invest directly in Cerus from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cerus stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cerus or CERS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cerus or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cerus shares which would translate to 0.514 fractional shares of Cerus as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cerus, in just a few clicks!

Returns in Cerus for Indian investors in Rupees

Investment Value

₹1,00,000

Cerus investment value today

Current value as on today

₹75,776

Returns

₹24,224

(-24.22%)

Returns from Cerus Stock

₹26,549 (-26.55%)

Dollar Returns

₹2,325 (+2.33%)

Indian investors sentiment towards Cerus

19%

Period: Sep 27, 2024 to Dec 26, 2024. Change in 30 Days versus previous period

Search volume for Cerus on INDmoney from India has grown in the last 30 days as on Dec 27, 2024. 19% more investors are searching Cerus in the last 30 days versus the previous period.

Global Institutional Holdings in Cerus

Baker Bros Advisors LP
10.49%
ARK Investment Management LLC
9.81%
BlackRock Inc
7.48%
Vanguard Group Inc
5.84%
PRIMECAP Management Company
4.60%
Wasatch Advisors LP
3.94%

Analyst Recommendation on Cerus

Buy

75%Buy

25%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Cerus(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cerus

What analysts predicted

Upside of 134.94%

Current:

$1.66

Target:

$3.90

Insights on Cerus

Price Movement
In the last 3 years, CERS stock has moved down by -77.3%
Increasing Revenue
Revenue is up for the last 3 quarters, 38.36M → 46.01M (in $), with an average increase of 8.5% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -9.68M → -2.93M (in $), with an average increase of 82.3% per quarter
CERS vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 62.7% return, outperforming this stock by 92.5%
CERS vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 113.2% return, outperforming this stock by 190.5%
Price to Sales
ForCERS every $1 of sales, investors are willing to pay $1.6, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Cerus Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$60.9M	↑ 39.8%
Net Income	$-57.6M	↓ 4.99%
Net Profit Margin	-94.51%	↑ 44.55%

	FY19	Y/Y Change
Revenue	$74.6M	↑ 22.56%
Net Income	$-71.2M	↑ 23.76%
Net Profit Margin	-95.44%	↓ 0.93%

	FY20	Y/Y Change
Revenue	$91.9M	↑ 23.14%
Net Income	$-59.9M	↓ 15.98%
Net Profit Margin	-65.12%	↑ 30.32%

	FY21	Y/Y Change
Revenue	$130.9M	↑ 42.36%
Net Income	$-54.4M	↓ 9.16%
Net Profit Margin	-41.55%	↑ 23.57%

	FY22	Y/Y Change
Revenue	$162.0M	↑ 23.83%
Net Income	$-42.8M	↓ 21.24%
Net Profit Margin	-26.43%	↑ 15.12%

	FY23	Y/Y Change
Revenue	$156.4M	↓ 3.51%
Net Income	$-37.5M	↓ 12.46%
Net Profit Margin	-23.98%	↑ 2.45%

	Q2 FY23	Q/Q Change
Revenue	$38.9M	↑ 25.44%
Net Income	$-13.3M	↓ 15.13%
Net Profit Margin	-34.17%	↑ 16.33%

	Q3 FY23	Q/Q Change
Revenue	$39.8M	↑ 2.37%
Net Income	$-7.3M	↓ 45.26%
Net Profit Margin	-18.27%	↑ 15.9%

	Q4 FY23	Q/Q Change
Revenue	$46.8M	↑ 17.59%
Net Income	$-1.3M	↓ 81.73%
Net Profit Margin	-2.84%	↑ 15.43%

	Q1 FY24	Q/Q Change
Revenue	$38.4M	↓ 17.97%
Net Income	$-9.7M	↑ 629.52%
Net Profit Margin	-25.25%	↓ 22.41%

	Q2 FY24	Q/Q Change
Revenue	$45.1M	↑ 17.5%
Net Income	$-5.8M	↓ 40.39%
Net Profit Margin	-12.81%	↑ 12.44%

	Q3 FY24	Q/Q Change
Revenue	$46.0M	↑ 2.08%
Net Income	$-2.9M	↓ 49.19%
Net Profit Margin	-6.38%	↑ 6.43%

	FY18	Y/Y Change
Profit	$29.3M	↑ 39.15%

	FY19	Y/Y Change
Profit	$41.2M	↑ 40.84%

	FY20	Y/Y Change
Profit	$50.8M	↑ 23.12%

	FY21	Y/Y Change
Profit	$67.4M	↑ 32.74%

	FY22	Y/Y Change
Profit	$87.1M	↑ 29.25%

	FY23	Y/Y Change
Profit	$86.4M	↓ 0.8%

	Q2 FY23	Q/Q Change
Profit	$21.3M	↑ 23.43%

	Q3 FY23	Q/Q Change
Profit	$21.8M	↑ 2.24%

	Q4 FY23	Q/Q Change
Profit	$25.3M	↑ 16.02%

	Q1 FY24	Q/Q Change
Profit	$21.3M	↓ 15.96%

	Q2 FY24	Q/Q Change
Profit	$24.7M	↑ 15.96%

	Q3 FY24	Q/Q Change
Profit	$26.2M	↑ 6.22%

	FY18	Y/Y Change
Operating Cash Flow	$-31.2M	↓ 40.18%
Investing Cash Flow	$-43.8M	↓ 10515.2%
Financing Cash Flow	$92.8M	↑ 115.7%

	FY19	Y/Y Change
Operating Cash Flow	$-65.8M	↑ 110.71%
Investing Cash Flow	$28.2M	↓ 164.28%
Financing Cash Flow	$43.5M	↓ 53.11%

	FY20	Y/Y Change
Operating Cash Flow	$-40.7M	↓ 38.12%
Investing Cash Flow	$-49.6M	↓ 275.83%
Financing Cash Flow	$91.8M	↑ 111.06%

	FY21	Y/Y Change
Operating Cash Flow	$-33.9M	↓ 16.74%
Investing Cash Flow	$12.7M	↓ 125.6%
Financing Cash Flow	$34.3M	↓ 62.64%

	FY22	Y/Y Change
Operating Cash Flow	$-25.6M	↓ 24.49%
Investing Cash Flow	$8.5M	↓ 33.29%
Financing Cash Flow	$4.2M	↓ 87.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-9.0M	↑ 5.84%
Investing Cash Flow	$2.3M	↓ 241.49%
Financing Cash Flow	$-173.0K	↓ 108.39%

Cerus Technicals Summary

Sell

Neutral

Buy

Cerus is currently in a neutral trading position according to technical analysis indicators.

Cerus Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cerus Corp	-13.19%	-10.23%	-30.09%	-76.7%	-61.74%
Stryker Corporation	-4.47%	8.97%	23.96%	36.93%	77.64%
Boston Scientific Corp.	0.35%	18.26%	61.82%	110.62%	102.42%
Edwards Lifesciences Corp.	4.59%	-18.39%	-1.73%	-41.72%	-2.7%
Abbott Laboratories	-3.52%	10.44%	3.95%	-18.3%	32.21%
Medtronic Plc	-5.48%	3.6%	-1.44%	-21.99%	-27.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cerus Corp	NA	NA	0.0	-0.11	-0.38	-0.04	NA	0.29
Stryker Corporation	39.7	39.7	2.56	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	75.26	75.26	1.65	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	29.1	29.1	6.92	2.55	0.19	0.11	NA	16.18
Abbott Laboratories	34.88	34.88	2.22	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.94	24.94	1.49	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cerus Corp	Buy	$293.4M	-61.74%	NA	-11.19%
Stryker Corporation	Buy	$141.3B	77.64%	39.7	16.34%
Boston Scientific Corp.	Buy	$134.2B	102.42%	75.26	11.26%
Edwards Lifesciences Corp.	Buy	$44.5B	-2.7%	29.1	65.86%
Abbott Laboratories	Buy	$199.0B	32.21%	34.88	13.99%
Medtronic Plc	Buy	$104.6B	-27.8%	24.94	12.06%

About Cerus

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.

Organization	Cerus
Employees	625
CEO	Mr. William M. Greenman
Industry	Health Technology

Management People of Cerus

Name	Title
Mr. William M. Greenman	President, CEO & Director
Mr. Kevin D. Green CPA	VP of Finance & CFO
Mr. Vivek K. Jayaraman	Chief Operating Officer
Ms. Chrystal Jensen J.D.	Chief Legal Officer & General Counsel
Dr. Richard J. Benjamin MBChB, Ph.D.	Chief Medical Officer
Dr. Laurence M. Corash M.D.	Co-Founder & Chief Scientific Officer
Mr. Matthew M. Notarianni	Senior Director of Investor Relations
Lainie Corten	Vice President of Global Marketing
Ms. Alicia Goodman	Chief Human Resources Officer
Ms. Carol M. Moore	Senior Vice President of Regulatory Affairs, Quality & Clinical

Important FAQs about investing in Cerus from India :

What is Cerus share price today?

Cerus share price today stands at $1.66, Open: $1.58 ; Previous Close: $1.58 ; High: $1.67 ; Low: $1.56 ; 52 Week High: $2.59 ; 52 Week Low: $1.38. The stock opens at $1.58, after a previous close of $1.58. The stock reached a daily high of $1.67 and a low of $1.56, with a 52-week high of $2.59 and a 52-week low of $1.38.

Can Indians buy Cerus shares?

Yes, Indians can invest in the Cerus (CERS) from India.

With INDmoney, you can buy Cerus at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cerus at zero transaction cost.

How can I buy Cerus shares from India?

It is very easy to buy Cerus from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cerus be purchased?

Yes, you can buy fractional shares of Cerus with INDmoney app.

What are the documents required to start investing in Cerus stocks?

To start investing in Cerus, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.